RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer
The DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.
Abstract
The genetic components of the RB:CDK:cyclin:p16 tumor suppressor pathway undergo mutational and epigenetic alterations in a wide range of human cancers and serve as critical targets for inactivation by the transforming oncoproteins of several DNA tumor viruses. Lung cancer has been a useful model system for these studies as it was the first tumor to demonstrate an important role for RB in the genesis of a common adult malignancy and was also the first human cancer to demonstrate genetic evidence for a multi-component RB:p16 tumor suppressor pathway. Lung tumorigenesis, however, is a complex disease process that requires longstanding carcinogen exposure in order to acquire somatic alterations at many distinct genetic loci. Understanding the multifunctional properties of RB to regulate cell proliferation, differentiation, and apoptosis and how they relate to the sequential accumulation of other clonal gene defects will be essential in order to understand the specific patterns of gene inactivation observed in different subtypes of lung cancer and to fulfill the promise of 'molecular target' therapeutics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A clear example that RB and p16 mutations are not equivalent comes from the observations that RB is mutated in most, if not all cases of SCLC, whereas p16 mutations are never found in this lung cancer type but are prevalent in non-SCLC, a different type of lung cancer167.”
From Cellular mechanisms of tumour suppression by the retinoblastoma gene (2008) · cites this paper as [167]
In the citing paper
“A clear example that RB and p16 mutations are not equivalent comes from the observations that RB is mutated in most, if not all cases of SCLC, whereas p16 mutations are never found in this lung cancer type but are prevalent in non-SCLC, a different type of lung cancer167.”
From Cellular mechanisms of tumour suppression by the retinoblastoma gene (2008) · cites this paper as [167]
In the citing paper
“A clear example that RB and p16 mutations are not equivalent comes from the observations that RB is mutated in most, if not all cases of SCLC, whereas p16 mutations are never found in this lung cancer type but are prevalent in non-SCLC, a different type of lung cancer167.”
From Cellular mechanisms of tumour suppression by the retinoblastoma gene (2008) · cites this paper as [167]
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · cited 2×
“…p21/p27/p57 Cip/Kip family of CDK2:cyclin E inhibitors (Grimison et al., 2000; Jiang et al., 1998; Sherr and Roberts, 1999), seemingly to both sequester inhibitory activity away from CDK2:cyclin E complexes and, perhaps, to stabilize CDK4/6:cyclin D activity (Sherr and Roberts, 1999) (Figure 1).”
BackgroundThe retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · cited 1×
“…et al., 1994), as a common site for homozygous deletions in tumor cell lines (Kamb et al., 1994), and as a negative regulator for the CDK4/6 kinase (Serrano et al., 1993) which phosphorylates RB in late G1, suggested that the p16 gene could be an important target for mutations in a wide range of…”
BackgroundA human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma
Friend, S. H., Bernards, R., Rogelj, S., Weinberg, R. A., Rapaport, J. M., Albert, D. M., & Dryja, T. P. (1986) · Nature · doi:10.1038/323643a0 · Cited by 2,948 · cited 1×
“Nonetheless, shortly after the validation of the RB gene as the locus that underlies the development of both familial and sporadic retinoblastoma (Friend et al., 1986; Lee et al., 1987), mutational inactivation of the RB gene was identified in approximately 90% of the common adult malignancy, small…”
BackgroundA cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751 · cited 2×
“The almost simultaneous description of the p16 gene as the locus conferring susceptibility familial melanoma (Kamb et al., 1994), as a common site for homozygous deletions in tumor cell lines (Kamb et al., 1994), and as a negative regulator for the CDK4/6 kinase (Serrano et al., 1993) which…”
BackgroundMost human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., & Perucho, M. (1988) · Cell · doi:10.1016/0092-8674(88)90571-5 · Cited by 2,114 · cited 1×
“…lung, and thyroid, they are rarely detected in the endocrine tumors that arise from these same organs and may occur in 0% of medullary thyroid cancer and in 0% of neuroendocrine small cell lung cancer (Almoguera et al., 1988; Bockhorn et al., 2000; Capella et al., 1996; Mitsudomi et al., 1991).”
BackgroundMerlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., & Sidransky, D. (1995) · Nature Medicine · doi:10.1038/nm0795-686 · Cited by 1,986 · cited 1×
“…in identifying acquired somatic p16 mutations in tumors resulted from the unexpected observation that the p16 gene preferentially undergoes tumor-specific epigenetic gene silencing through promoter and exon 1 hypermethylation (Herman et al., 1995; Merlo et al., 1995; Otterson et al., 1995).”
BackgroundEffects of an Rb mutation in the mouse
Jacks, T., Fazeli, A., Schmitt, E. M., Bronson, R. T., Goodell, M. A., & Weinberg, R. A. (1992) · Nature · doi:10.1038/359295a0 · Cited by 1,755 · cited 1×
“For example, the major defect underlying the embryonic lethality of RB null mice can be primarily localized to selected regions of ectopic cell proliferation/apoptosis within neural tissues (Jacks et al., 1992; Lee et al., 1992).”
BackgroundThe Molecular Genetics of Cancer
Bishop, J. M. (1987) · Science · doi:10.1126/science.3541204 · Cited by 1,688
Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis
Lee, E. Y.-H. P., Chang, C.-Y., Hu, N., Wang, Y.-C. J., Lai, C.-C., Herrup, K., Lee, W.-H., & Bradley, A. (1992) · Nature · doi:10.1038/359288a0 · Cited by 1,265 · cited 1×
“For example, the major defect underlying the embryonic lethality of RB null mice can be primarily localized to selected regions of ectopic cell proliferation/apoptosis within neural tissues (Jacks et al., 1992; Lee et al., 1992).”
BackgroundThe Rb/E2F pathway: expanding roles and emerging paradigms
Harbour, J. W., & Dean, D. C. (2000) · Genes & Development · doi:10.1101/gad.813200 · Cited by 1,153 · cited 2×
“The broad question of how the RB gene pathway may mediate tumor suppressor effects and how to restore RB function in tumor cells is a critical topic in cancer research and has also been the subject of many recent reviews (Harbour and Dean, 2000; Sellers and Kaelin, 1997; Sherr, 2001).”
BackgroundCheng, M., Olivier, P., Diehl, J. A., Fero, M., Roussel, M. F., Roberts, J. M., & Sherr, C. J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1571 · Cited by 1,142 · cited 1×
“Elevated p16 in turn binds to CDK4:cyclinD complexes to disrupt a critical stabilizing effect of bound p27Kip, which can then result in the loss of steady-state cyclin D1 levels (Cheng et al., 1999; Parry et al., 1995).”
BackgroundThe INK4a/ARF network in tumour suppression
Sherr, C. J. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35096061 · Cited by 996 · cited 2×
“It is important to note that inactivation of the parallel and interconnecting p14ARF/p53 axis is also essential in these RB(7) lung cells in order to bypass efficient apoptosis as reviewed elsewhere (Sherr, 2001).”
BackgroundChen, P.-L., Scully, P., Shew, J.-Y., Wang, J. Y. J., & Lee, W.-H. (1989) · Cell · doi:10.1016/0092-8674(89)90517-5 · Cited by 952 · cited 1×
“…status with specific stages of the cell cycle such that RB was predominantly hypophosphorylated in resting cells, in terminally differentiated cells, and in cells that were arrested before the G1/S transition into DNA synthesis (Chen et al., 1989; Decaprio et al., 1989; Mihara et al., 1989).”
BackgroundSpecific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934 · cited 3×
“…the resistance of cyclin D1 null murine breast tissues to the tumorigenic effects of neu over-expression, but not to the effects of ectopic Myc (Yu et al., 2001), also correlates with the absence of neu amplification (Franklin et al., 2002; Hirsch et al., 2002), but the frequent…”
BackgroundInfluentialAbnormalities in Structure and Expression of the Human Retinoblastoma Gene in SCLC
Harbour, J. W., Lai, S.-L., Whang-Peng, J., Gazdar, A. F., Minna, J. D., & Kaye, F. J. (1988) · Science · doi:10.1126/science.2838909 · Cited by 902 · cited 2×
“The RB gene was the first tumor suppressor gene implicated in the etiology of lung cancer (Harbour et al., 1988; Yokota et al., 1988) and the evidence linking alterations of RB activity with human lung tumorigenesis is unequivocal.”
BackgroundSelf-citationDeCaprio, J. A., Ludlow, J. W., Lynch, D., Furukawa, Y., Griffin, J., Piwnica-Worms, H., Huang, C.-M., & Livingston, D. M. (1989) · Cell · doi:10.1016/0092-8674(89)90507-2 · Cited by 897 · cited 2×
“…status with specific stages of the cell cycle such that RB was predominantly hypophosphorylated in resting cells, in terminally differentiated cells, and in cells that were arrested before the G1/S transition into DNA synthesis (Chen et al., 1989; Decaprio et al., 1989; Mihara et al., 1989).”
BackgroundExpression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties
Kaelin, W. G., Krek, W., Sellers, W. R., DeCaprio, J. A., Ajchenbaum, F., Fuchs, C. S., Chittenden, T., Li, Y., Farnham, P. J., Blanar, M. A., et al. (1992) · Cell · doi:10.1016/0092-8674(92)90108-o · Cited by 819 · cited 1×
“This model was subsequently confirmed by the identification of a small group of nuclear RB pocket proteins (Kaelin et al., 1991, 1992) that have now expanded to a disparate family of over 100 members (Morris and Dyson, 2001).”
MethodCyclin D-dependent kinases, INK4 inhibitors and cancer
Ortega, S., Malumbres, M., & Barbacid, M. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00037-9 · Cited by 778
Physical interaction of the retinoblastoma protein with human D cyclins
Dowdy, S. F., Hinds, P. W., Louie, K., Reed, S. I., Arnold, A., & Weinberg, R. A. (1993) · Cell · doi:10.1016/0092-8674(93)90137-f · Cited by 744 · cited 1×
“In fact, the specific role for cyclin D during the G1 phase of the cell cycle is still controversial (Dowdy et al., 1993; Ezhevsky et al., 2001; Geng et al., 1999; Ho and Dowdy, 2002).”
BackgroundLee, W.-H., Shew, J.-Y., Hong, F. D., Sery, T. W., Donoso, L. A., Young, L.-J., Bookstein, R., & Lee, E. Y.-H. P. (1987) · Nature · doi:10.1038/329642a0 · Cited by 628 · cited 1×
“…after the validation of the RB gene as the locus that underlies the development of both familial and sporadic retinoblastoma (Friend et al., 1986; Lee et al., 1987), mutational inactivation of the RB gene was identified in approximately 90% of the common adult malignancy, small cell lung cancer…”
BackgroundMortality From Second Tumors Among Long-Term Survivors of Retinoblastoma
Eng, C., Li, F. P., Abramson, D. H., Ellsworth, R. M., Wong, F. L., Goldman, M. B., Seddon, J., Tarbell, N., & Boice, J. D. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.14.1121 · Cited by 568 · cited 1×
“…(RB) gene tumor suppressor pathway in human cancer since survivors of familial retinoblastoma were not previously known to develop lung tumors with any appreciable frequency (Eng et al., 1993) and the RB gene was initially believed to be linked only with a limited range of rare pediatric tumors.”
BackgroundHorowitz, J. M., Park, S. H., Bogenmann, E., Cheng, J. C., Yandell, D. W., Kaye, F. J., Minna, J. D., Dryja, T. P., & Weinberg, R. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.7.2775 · Cited by 530 · cited 1×
“In each of these cases, however, a deletion or missense mutation was localized within the RB functional ‘pocket’ domain and was found to have specifically inactivated the tumor suppressor activity of RB (Horowitz et al., 1990; Kaye et al., 1990).”
BackgroundSelf-citationKaelin, W. G., Pallas, D. C., DeCaprio, J. A., Kaye, F. J., & Livingston, D. M. (1991) · Cell · doi:10.1016/0092-8674(91)90236-r · Cited by 518 · cited 1×
“This model was subsequently confirmed by the identification of a small group of nuclear RB pocket proteins (Kaelin et al., 1991, 1992) that have now expanded to a disparate family of over 100 members (Morris and Dyson, 2001).”
MethodSelf-citationTumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition
Koh, J., Enders, G. H., David Dynlacht, B., & Harlow, E. (1995) · Nature · doi:10.1038/375506a0 · Cited by 516 · cited 1×
“While this prediction was soon confirmed (Koh et al., 1995), the model of p16 as an exclusive regulator of activated cyclin D may be vastly oversimplified.”
ResultLudlow, J. W., DeCaprio, J. A., Huang, C.-M., Lee, W.-H., Paucha, E., & Livingston, D. M. (1989) · Cell · doi:10.1016/0092-8674(89)90983-5 · Cited by 494 · cited 1×
“The second observation was the ability of the SV40 large T antigen to bind preferentially to the hypophosphorylated form of RB (Ludlow et al., 1989).”
BackgroundPreclinical and Clinical Development of Cyclin-Dependent Kinase Modulators
Senderowicz, A. M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.5.376 · Cited by 492 · cited 1×
“…that are linked to understanding the clinical/biological relevance of replacing p16 function by either using small CDK inhibitor-like analogues (Senderowicz and Sausville, 2000) in an attempt to regulate RB function or by testing methylation or DNA chromatin altering agents that may reverse…”
BackgroundYokota, J., Wada, M., Shimosato, Y., Terada, M., & Sugimura, T. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.24.9252 · Cited by 480 · cited 1×
“…experiments were undertaken because of evidence showing both cytogenetic alterations (Harbour et al., 1988) and loss of heterozygosity allele loss (Yokota et al., 1987) near the 13q14 locus of the RB gene, the finding that the RB gene might also encode rate-limiting tumor suppressor activity for…”
BackgroundPathways governing G1/S transition and their response to DNA damage
Bartek, J., & Lukas, J. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02114-7 · Cited by 471
Expression and amplification of the N-myc gene in primary retinoblastoma
Lee, W.-H., Murphree, A. L., & Benedict, W. F. (1984) · Nature · doi:10.1038/309458a0 · Cited by 453 · cited 1×
“Both tumor cell types are also known to over-express the N-myc gene in a subset of their cancers (Lee et al., 1984; Nau et al., 1986) and both exhibit the unusual and characteristic property of growing in cell culture in vitro as floating spheroid clusters of 50 – 200 cells.”
BackgroundCell cycle dependent regulation of phosphorylation of the human retinoblastoma gene product
Mihara, K., Cao, X.-R., Yen, A., Chandler, S., Driscoll, B., Murphree, A. L., T'Ang, A., & Fung, Y.-K. (1989) · Science · doi:10.1126/science.2588006 · Cited by 449
Rates of p16 ( MTS1 ) Mutations in Primary Tumors with 9p Loss
Cairns, P., Mao, L., Merlo, A., Lee, D. J., Schwab, D., Eby, Y., Tokino, K., van der Riet, P., Blaugrund, J. E., & Sidransky, D. (1994) · Science · doi:10.1126/science.8023167 · Cited by 427 · cited 1×
“The inability to detect acquired somatic mutations in primary tumors within the p16 gene, however, led to initial skepticism on the role of p16 as a valid tumor suppressor gene (Cairns et al., 1994; Spruck et al., 1994).”
BackgroundThe retinoblastoma gene family in differentiation and development
Lipinski, M. M., & Jacks, T. (1999) · Oncogene · doi:10.1038/sj.onc.1203244 · Cited by 405 · cited 1×
“In contrast, the loss of p16 is predicted to disrupt the ‘pocket’ binding function of all members of the RB pocket family, including RB, p107, and p130 (Lipinski and Jacks, 1999; Nevins, 1998).”
BackgroundReciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines.
Shapiro, G. I., Edwards, C. D., Kobzik, L., Godleski, J. J., Richards, W. G., Sugarbaker, D. J., & Rollins, B. J. (1995) · PubMed · Cited by 376
Cooperative tumorigenic effects of germline mutations in Rb and p53
Williams, B. O., Remington, L., Albert, D. M., Mukai, S., Bronson, R. T., & Jacks, T. (1994) · Nature Genetics · doi:10.1038/ng0894-480 · Cited by 368 · cited 1×
“…tumors including islet cell tumors of the pancreas, adrenal pheochromocytomas, medullary thyroid cancer, and pituitary tumors which resembles a mixture of both familial multiple endocrine neoplasia (MEN)-1 and MEN-2 syndromes (Coxon et al., 1998; Harvey et al., 1995; Williams et al., 1994).”
BackgroundParry, D., Bates, S., Mann, D. J., & Peters, G. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07026.x · Cited by 354 · cited 1×
“Elevated p16 in turn binds to CDK4:cyclinD complexes to disrupt a critical stabilizing effect of bound p27Kip, which can then result in the loss of steady-state cyclin D1 levels (Cheng et al., 1999; Parry et al., 1995).”
BackgroundRetinoblastoma protein partners
(2001) · Advances in Cancer Research · doi:10.1016/s0065-230x(01)82001-7 · Cited by 349 · cited 1×
“This model was subsequently confirmed by the identification of a small group of nuclear RB pocket proteins (Kaelin et al., 1991, 1992) that have now expanded to a disparate family of over 100 members (Morris and Dyson, 2001).”
MethodRescue of Cyclin D1 Deficiency by Knockin Cyclin E
Geng, Y., Whoriskey, W., Park, M. Y., Bronson, R. T., Medema, R. H., Li, T., Weinberg, R. A., & Sicinski, P. (1999) · Cell · doi:10.1016/s0092-8674(00)80788-6 · Cited by 336 · cited 1×
“In fact, the specific role for cyclin D during the G1 phase of the cell cycle is still controversial (Dowdy et al., 1993; Ezhevsky et al., 2001; Geng et al., 1999; Ho and Dowdy, 2002).”
BackgroundSignaling Networks That Link Cell Proliferation and Cell Fate
Sears, R. C., & Nevins, J. R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.r100063200 · Cited by 336
P16 gene in uncultured tumours
Spruck, C. H., Gonzalez-Zulueta, M., Shibata, A., Simoneau, A. R., Lin, M.-F., Gonzales, F., Tsai, Y. C., & Jones, P. A. (1994) · Nature · doi:10.1038/370183a0 · Cited by 318 · cited 1×
“The inability to detect acquired somatic mutations in primary tumors within the p16 gene, however, led to initial skepticism on the role of p16 as a valid tumor suppressor gene (Cairns et al., 1994; Spruck et al., 1994).”
BackgroundNuovo, G. J., Plaia, T. W., Belinsky, S. A., Baylin, S. B., & Herman, J. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12754 · Cited by 314 · cited 1×
“…in situ samples confirm this sequential requirement and show that RB and p16 genetic or epigenetic alterations are very early events in lung cancer (Nuovo et al., 1999; Park et al., 1999; Zochbauer-Muller et al., 2002), while Ras mutations develop later in the course of tumorigenesis (Sugio et…”
BackgroundEpidermal growth factor receptor family in lung cancer and premalignancy
Franklin, W. A., Veve, R., Hirsch, F. R., Helfrich, B. A., & Bunn, P. A. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.31520 · Cited by 306 · cited 1×
“…effects of neu over-expression, but not to the effects of ectopic Myc (Yu et al., 2001), also correlates with the absence of neu amplification (Franklin et al., 2002; Hirsch et al., 2002), but the frequent over-expression of Myc in small cell lung cancer samples (Johnson et al., 1988), It is…”
BackgroundHuman small-cell lung cancers show amplification and expression of the N-myc gene.
Nau, M. M., Brooks, B. J., Carney, D. N., Gazdar, A. F., Battey, J. F., Sausville, E. A., & Minna, J. D. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.4.1092 · Cited by 293 · cited 1×
“Both tumor cell types are also known to over-express the N-myc gene in a subset of their cancers (Lee et al., 1984; Nau et al., 1986) and both exhibit the unusual and characteristic property of growing in cell culture in vitro as floating spheroid clusters of 50 – 200 cells.”
BackgroundRole of the retinoblastoma protein in the pathogenesis of human cancer.
Sellers, W. R., & Kaelin, W. G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.11.3301 · Cited by 253 · cited 1×
“The broad question of how the RB gene pathway may mediate tumor suppressor effects and how to restore RB function in tumor cells is a critical topic in cancer research and has also been the subject of many recent reviews (Harbour and Dean, 2000; Sellers and Kaelin, 1997; Sherr, 2001).”
BackgroundMolecular Pathogenesis of Lung Cancer
Zöchbauer-Müller, S., Gazdar, A. F., & Minna, J. D. (2002) · Annual Review of Physiology · doi:10.1146/annurev.physiol.64.081501.155828 · Cited by 209
Ezhevsky, S. A., Ho, A., Becker-Hapak, M., Davis, P. K., & Dowdy, S. F. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.14.4773-4784.2001 · Cited by 207 · cited 1×
“In fact, the specific role for cyclin D during the G1 phase of the cell cycle is still controversial (Dowdy et al., 1993; Ezhevsky et al., 2001; Geng et al., 1999; Ho and Dowdy, 2002).”
BackgroundKaye, F. J., Kratzke, R. A., Gerster, J. L., & Horowitz, J. M. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6922 · Cited by 201 · cited 1×
“In each of these cases, however, a deletion or missense mutation was localized within the RB functional ‘pocket’ domain and was found to have specifically inactivated the tumor suppressor activity of RB (Horowitz et al., 1990; Kaye et al., 1990).”
BackgroundSelf-citationMice deficient in both p53 and Rb develop tumors primarily of endocrine origin.
Harvey, M., Vogel, H. S., Lee, E. Y.-H. P., Bradley, A., & Donehower, L. A. (1995) · PubMed · Cited by 201
Regulation of G1 cell-cycle progression by oncogenes and tumor suppressor genes
Ho, A. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00263-5 · Cited by 192 · cited 1×
“In fact, the specific role for cyclin D during the G1 phase of the cell cycle is still controversial (Dowdy et al., 1993; Ezhevsky et al., 2001; Geng et al., 1999; Ho and Dowdy, 2002).”
BackgroundRegulation of the retinoblastoma tumor suppressor protein by cyclin/cdks
Adams, P. D. (2001) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(01)00019-1 · Cited by 176 · cited 1×
“In addition, although RB is maximally phosphorylated by sequential cyclin D and cyclin E phosphorylation (Adams, 2001) and RB status has been inversely correlated only with p16 protein expression in lung cancer, the possibility still exists that the deregulated phosphorylation of another unknown…”
BackgroundK-ras mutations are a relatively late event in the pathogenesis of lung carcinomas
(1995) · Lung Cancer · doi:10.1016/0169-5002(95)98722-m · Cited by 166 · cited 1×
“…samples confirm this sequential requirement and show that RB and p16 genetic or epigenetic alterations are very early events in lung cancer (Nuovo et al., 1999; Park et al., 1999; Zochbauer-Muller et al., 2002), while Ras mutations develop later in the course of tumorigenesis (Sugio et al., 1994).”
BackgroundWeiser, T. S., Guo, Z. S., Ohnmacht, G. A., Parkhurst, M. L., Tong-On, P., Marincola, F. M., Fischette, M. R., Yu, X., Chen, G. A., Hong, J. A., et al. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200103000-00010 · Cited by 162 · cited 1×
“…analogues (Senderowicz and Sausville, 2000) in an attempt to regulate RB function or by testing methylation or DNA chromatin altering agents that may reverse epigenetic gene silencing of candidate tumor suppressor genes such as p16 in lung cancer (Momparler and Ayoub, 2001; Weiser et al., 2001).”
BackgroundZalvide, J., Stubdal, H., & DeCaprio, J. A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.3.1408 · Cited by 150 · cited 1×
“…of p107 and p130 mutations in lung cancer samples, however, it is still plausible that the simultaneously inactivation all three pocket RB members, through loss of p16 function, could confer an enhanced proliferative signal as compared with RB alone (Classon et al., 2000; Zalvide et al., 1998).”
BackgroundMultiple Clonal Abnormalities in the Bronchial Epithelium of Patients With Lung Cancer
Park, I., Wistuba, I. I., Maitra, A., Milchgrub, S., Virmani, A. K., Minna, J. D., & Gazdar, A. F. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.21.1863 · Cited by 150 · cited 1×
“…samples confirm this sequential requirement and show that RB and p16 genetic or epigenetic alterations are very early events in lung cancer (Nuovo et al., 1999; Park et al., 1999; Zochbauer-Muller et al., 2002), while Ras mutations develop later in the course of tumorigenesis (Sugio et al., 1994).”
BackgroundNon-ocular cancer in relatives of retinoblastoma patients
Sanders, B., Jay, M., Draper, G., & Roberts, E. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.285 · Cited by 135 · cited 1×
“Nonetheless, some studies have suggested a 10-fold increase rate of lung cancer (and in particular small cell lung cancer) in first degree relatives of patients with familial retinoblastoma (Sanders et al., 1989).”
BackgroundThird (fourth and fifth) nonocular tumors in survivors of retinoblastoma
Abramson, D. H., Melson, M. R., Dunkel, I. J., & Frank, C. M. (2001) · Ophthalmology · doi:10.1016/s0161-6420(01)00713-8 · Cited by 129 · cited 1×
“…retinoblastoma, however, do not generally survive the additional 30 – 40 years due to death from an increasing incidence of second nonocular malignancies, usually from sarcomas within radiotherapy ports (Abramson et al., 2001), and may abuse tobacco at a much lower rate than the general population.”
BackgroundLoss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma
Helin, K., Holm, K., Niebuhr, A., Eiberg, H., Tommerup, N., Hougaard, S., Poulsen, H. S., Spang-Thomsen, M., & Nørgaard, P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6933 · Cited by 128 · cited 1×
“The role of p107 and p130 in lung cancer, however, is uncertain as only one small cell lung cancer cell line has been detected with a p130 alteration (Helin et al., 1997) and other studies have shown no alterations (Modi et al., 2000).”
ResultCombinatorial roles for pRB, p107, and p130 in E2F-mediated cell cycle control
Classon, M., Salama, S., Gorka, C., Mulloy, R., Braun, P., & Harlow, E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190343497 · Cited by 115 · cited 1×
“…of p107 and p130 mutations in lung cancer samples, however, it is still plausible that the simultaneously inactivation all three pocket RB members, through loss of p16 function, could confer an enhanced proliferative signal as compared with RB alone (Classon et al., 2000; Zalvide et al., 1998).”
BackgroundRequirement of Cyclin E-Cdk2 Inhibition in p16 INK4a -Mediated Growth Suppression
Jiang, H., Chou, H. S., & Zhu, L. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.9.5284 · Cited by 113 · cited 3×
“Since inhibition of cyclin E activity, but not cyclin D, can induce G1 arrest of proliferating cells, the indirect suppression of CDK2:cyclin E by p27Kip1 may be the primary growth suppressor function mediated by p16 induction (Jiang et al., 1998).”
BackgroundInfluentialHow many tumor suppressor genes are involved in human lung carcinogenesis?
Kohno, T. (1999) · Carcinogenesis · doi:10.1093/carcin/20.8.1403 · Cited by 105 · cited 1×
“…assays as a functional screening tool, and the uncertain role of hypermethylation and haploinsufficiency as reliable markers for the identification of increasing number of candidate tumor suppressor genes (Eng et al., 2000; Kaye and Kubo, 2001; Kohno and Yokota, 1999; Tomizawa et al., 1998).”
BackgroundHER2/neu expression in malignant lung tumors
Hirsch, F. R., Franklin, W. A., Veve, R., Varella‐Garcia, M., & Bunn, P. A. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.31523 · Cited by 102 · cited 1×
“…but not to the effects of ectopic Myc (Yu et al., 2001), also correlates with the absence of neu amplification (Franklin et al., 2002; Hirsch et al., 2002), but the frequent over-expression of Myc in small cell lung cancer samples (Johnson et al., 1988), It is possible to speculate…”
Backgroundmyc family DNA amplification in small cell lung cancer patients' tumors and corresponding cell lines
Johnson, B. E. (1989) · Lung Cancer · doi:10.1016/0169-5002(89)90322-x · Cited by 101 · cited 1×
“…of neu amplification (Franklin et al., 2002; Hirsch et al., 2002), but the frequent over-expression of Myc in small cell lung cancer samples (Johnson et al., 1988), It is possible to speculate that the absence of amplification of other related epidermal growth factor-like receptors in small…”
BackgroundRB and the cell cycle: Entrance or exit?
Cooper, J. A., & Whyte, P. (1989) · Cell · doi:10.1016/0092-8674(89)90495-9 · Cited by 96 · cited 1×
“…where hypophosphorylated RB represents the ‘active’ tumor suppressor form of RB that can tightly bind to a family of cellular proteins to prevent entry into mitosis (Cooper and Whyte, 1989; Decaprio et al., 1989) which DNA tumor viruses subsequently try to disrupt to promote viral replication.”
BackgroundCagle, P. T., El‐Naggar, A. K., Xu, H., Hu, S., & Benedict, W. F. (1997) · Europe PMC (PubMed Central) · Cited by 92
Momparler, R. L., & Ayoub, J. (2001) · Lung Cancer · doi:10.1016/s0169-5002(01)00397-x · Cited by 89 · cited 1×
“…analogues (Senderowicz and Sausville, 2000) in an attempt to regulate RB function or by testing methylation or DNA chromatin altering agents that may reverse epigenetic gene silencing of candidate tumor suppressor genes such as p16 in lung cancer (Momparler and Ayoub, 2001; Weiser et al., 2001).”
BackgroundKelley, M. J., Nakagawa, K., Steinberg, S. M., Mulshine, J. L., Kamb, A., & Johnson, B. E. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.10.756 · Cited by 80 · cited 2×
“…of a remarkably tight inverse correlation between mutational inactivation of RB and the loss of p16 protein expression in lung cancer (Kelley et al., 1995a; Otterson et al., 1994; Shapiro et al., 1995), however, predicted that the association of p16 inactivation with primary lung…”
BackgroundEaston, J. B., Wei, T., Lahti, J. M., & Kidd, V. J. (1998) · PubMed · Cited by 78
Hereditary Retinoblastoma and Risk of Lung Cancer
Kleinerman, R. A. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.24.2037 · Cited by 76 · cited 1×
“…retinoblastoma registry, that had now followed 139 subjects who had survived to age 40, found an increased risk of lung cancer in this group (Kleinerman et al., 2000) and concluded that lung cancer is an established risk for retinoblastoma survivors that is independent of prior radiation…”
BackgroundPonder, B. A. J. (1992) · BMJ · doi:10.1136/bmj.304.6836.1234 · Cited by 68
Ras Oncogene Mutations in Thyroid Tumors
Capellá, G., Matías‐Guiu, X., Ampudia, X., de Leiva, A., Perucho, M., & Prat, J. (1996) · Diagnostic Molecular Pathology · doi:10.1097/00019606-199603000-00008 · Cited by 66 · cited 1×
“…lung, and thyroid, they are rarely detected in the endocrine tumors that arise from these same organs and may occur in 0% of medullary thyroid cancer and in 0% of neuroendocrine small cell lung cancer (Almoguera et al., 1988; Bockhorn et al., 2000; Capella et al., 1996; Mitsudomi et al., 1991).”
BackgroundA bird's eye view of global methylation
Eng, C., Herman, J. G., & Baylin, S. B. (2000) · Nature Genetics · doi:10.1038/72730 · Cited by 62 · cited 1×
“…assays as a functional screening tool, and the uncertain role of hypermethylation and haploinsufficiency as reliable markers for the identification of increasing number of candidate tumor suppressor genes (Eng et al., 2000; Kaye and Kubo, 2001; Kohno and Yokota, 1999; Tomizawa et al., 1998).”
BackgroundFalco, J., Baylin, S. B., Lupu, R., Borges, M. W., Nelkin, B. D., Jasti, R., Davidson, N. E., & Mabry, M. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114630 · Cited by 52 · cited 1×
“Alternatively, a multipotent lung cancer progenitor cell target might differentiate along different cell lineage pathways depending on the Oncogene expression patterns of different activated oncogenes/ tumor suppressor genes (Falco et al., 1990).”
BackgroundModi, S., Kubo, A., Oie, H. K., Coxon, A. B., Rehmatulla, A., & Kaye, F. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203815 · Cited by 50 · cited 2×
“The role of p107 and p130 in lung cancer, however, is uncertain as only one small cell lung cancer cell line has been detected with a p130 alteration (Helin et al., 1997) and other studies have shown no alterations (Modi et al., 2000).”
BackgroundResultSelf-citationCDKN2 in HPV‐positive and HPV‐negative cervical‐carcinoma cell lines
Kelley, M. J., Otterson, G. A., Kaye, F. J., Popescu, N. C., Johnson, B. E., & DiPaolo, J. A. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910630214 · Cited by 43 · cited 2×
“…of a remarkably tight inverse correlation between mutational inactivation of RB and the loss of p16 protein expression in lung cancer (Kelley et al., 1995a; Otterson et al., 1994; Shapiro et al., 1995), however, predicted that the association of p16 inactivation with primary lung…”
BackgroundSelf-citationRET cooperates with RB/p53 inactivation in a somatic multi-step model for murine thyroid cancer
Coxon, A. B., Ward, J. M., Geradts, J., Otterson, G. A., Zajac‐Kaye, M., & Kaye, F. J. (1998) · Oncogene · doi:10.1038/sj.onc.1202381 · Cited by 40 · cited 1×
“…tumors including islet cell tumors of the pancreas, adrenal pheochromocytomas, medullary thyroid cancer, and pituitary tumors which resembles a mixture of both familial multiple endocrine neoplasia (MEN)-1 and MEN-2 syndromes (Coxon et al., 1998; Harvey et al., 1995; Williams et al., 1994).”
BackgroundSelf-citationOrigin of Human Small Cell Lung Cancer
Gazdar, A. F., Bunn, P. A., Minna, J. D., & Baylin, S. B. (1985) · Science · doi:10.1126/science.2992083 · Cited by 32 · cited 1×
“For example, although there still remains uncertainty about the cell of origin for small cell lung cancer (Gazdar et al., 1985), both tumors are believed to arise from a similar progenitor neural crest origin and both tumors synthesize a variety of neuroendocrine enzymes and markers.”
BackgroundAbsence of H- and K-ras oncogene mutations in sporadic medullary thyroid carcinoma
Bockhorn, M., Frilling, A., Калинин, В. Н., Schröder, S., & Broelsch, C. E. (2012) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0032-1329215 · Cited by 17
Identification and Characterization of Families with Aggregation of Lung Cancer
Tomizawa, Y., Adachi, J.-I., Kohno, T., Yamaguchi, N., Saito, R., & Yokota, J. (1998) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/28.3.192 · Cited by 12 · cited 1×
“…assays as a functional screening tool, and the uncertain role of hypermethylation and haploinsufficiency as reliable markers for the identification of increasing number of candidate tumor suppressor genes (Eng et al., 2000; Kaye and Kubo, 2001; Kohno and Yokota, 1999; Tomizawa et al., 1998).”
BackgroundSteel, C. (1996) · Molecular Medicine Today · doi:10.1016/s1357-4310(96)80011-6 · Cited by 7
Cited by
van Meerbeeck, J. P., Fennell, D. A., & De Ruysscher, D. K. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60165-7 · Cited by 1,237
Cellular mechanisms of tumour suppression by the retinoblastoma gene
Burkhart, D. L., & Sage, J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2399 · Cited by 974
Small cell lung cancer: Where do we go from here?
Byers, L. A., & Rudin, C. M. (2015) · Cancer · doi:10.1002/cncr.29098 · Cited by 636
Targeting protein prenylation for cancer therapy
Berndt, N., Hamilton, A. D., & Sebti, S. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3151 · Cited by 614
Byers, L. A., Wang, J., Nilsson, M. B., Fujimoto, J., Saintigny, P., Yordy, J., Giri, U., Peyton, M., Fan, Y. H., Diao, L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0112 · Cited by 557
Metadata
- Authors
- Kaye, F. J.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Kaye, Frederic J
- ORCID
- Kaye, Frederic J
- Venue
- Oncogene
- Published
- 2002-10-04
- Volume
- 21
- Issue
- 45
- Pages
- 6908-6914
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2081412587
- Cited by
- 153
- References
- 80
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 5 · 2020: 7 · 2019: 5 · 2018: 5 · 2017: 7 · 2016: 2 · 2015: 5 · 2014: 13 · 2013: 5 · 2012: 4
- FWCI
- 0.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- retinoblastoma protein, cyclin-dependent kinases, p16, tumor suppressor pathways, lung cancer, lung carcinogenesis, gene inactivation, epigenetic modifications, DNA tumor viruses, carcinogen exposure, targeted therapy
- MeSH terms
- Humans, Lung Neoplasms, Proto-Oncogene Proteins, Genes, Retinoblastoma, Gene Deletion, Carcinoma, Small Cell, Cyclin-Dependent Kinases, Genes, p16, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.